Moderna Taiwan Co (莫德納台灣) has begun recruiting participants for its flu vaccine trial and expects to disclose the results in March next year, the company said yesterday.
Taiwan is the only Asian country where US-based Moderna Inc is conducting clinical trials for its flu vaccine.
Moderna Taiwan is collaborating with eight hospitals or medical centers for the enrollment, but it has not set a target number of participants as the clinical trial uses competitive enrollment, which means when a target number of subjects have been meet, all enrollment ceases, general manager Joyce Lee (李宜真) told a media briefing in Taipei.
Photo: EPA-EFE
“We should be able to have some readout of the human test in March next year. This [rate of human test] is comparatively high, as speed is in the DNA of Moderna, which utilizes messenger RNA technology,” Lee said.
Taiwan is also the first Asian market to introduce Moderna’s BA.4/BA.5-adapted bivalent vaccine for COVID-19, she added.
Moderna Taiwan aims to introduce the latest mRNA technology to Taiwan and would try to participate in as many multination clinical trials by its parent company as possible, Lee said.
Launched in September, Moderna Taiwan is recruiting more staff for business and marketing, with an eye to increasing the number of employees to 10 next year, Lee said.
Asked if Moderna would continue supplying Taiwan with its latest COVID-19 vaccine, Patrick Bergstedt, Moderna’s senior vice president and head of emerging markets, said that the company is in talks with all stakeholders, including the Ministry of Health and Welfare.
“We need to remember that we are not dealing with the same coronavirus that caused the pandemic in 2020 — the virus has evolved,” Bergstedt said.
The world cannot assume that COVID-19 will be the last global pandemic, so Moderna is researching and developing vaccines for 15 viruses that are emerging or have been ignored, but might cause the greatest health threat to human beings by 2025, Bergstedt said.
Overall, Moderna would focus on respiratory viruses, he said.
The company is also researching non-invasive vaccines, which might be administered in the form of a nasal spray or patch, he added.
ASML Holding NV’s new advanced chip machines have a daunting price tag, said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), one of the Dutch company’s biggest clients. “The cost is very high,” TSMC senior vice president Kevin Zhang (張曉強) said at a technology symposium in Amsterdam on Tuesday, referring to ASML’s latest system known as high-NA extreme ultraviolet (EUV). “I like the high-NA EUV’s capability, but I don’t like the sticker price,” Zhang said. ASML’s new chip machine can imprint semiconductors with lines that are just 8 nanometers thick — 1.7 times smaller than the previous generation. The machines cost 350 million euros (US$378 million)
Apple Inc has closed in on an agreement with OpenAI to use the start-up’s technology on the iPhone, part of a broader push to bring artificial intelligence (AI) features to its devices, people familiar with the matter said. The two sides have been finalizing terms for a pact to use ChatGPT features in Apple’s iOS 18, the next iPhone operating system, said the people, who asked not to be identified because the situation is private. Apple also has held talks with Alphabet Inc’s Google about licensing its Gemini chatbot. Those discussions have not led to an agreement, but are ongoing. An OpenAI
INSATIABLE: Almost all AI innovators are working with the chipmaker to address the rapidly growing AI-related demand for energy-efficient computing power, the CEO said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported about 60 percent annual growth in revenue for last month, benefiting from rapidly growing demand for artificial intelligence (AI) and high-performance computing applications. Revenue last month expanded to NT$236.02 billion (US$7.28 billion), compared with NT$147.9 billion in April last year, the second-highest level in company history, TSMC said in a statement. On a monthly basis, revenue surged 20.9 percent, from NT$195.21 billion in March. As AI-related applications continue to show strong growth, TSMC expects revenue to expand about 27.6 percent year-on-year during the current quarter to between US$19.6 billion and US$20.4 billion. That would
‘FULL SUPPORT’: Kumamoto Governor Takashi Kimura said he hopes more companies would settle in the prefecture to create an area similar to Taiwan’s Hsinchu Science Park The newly elected governor of Japan’s Kumamoto Prefecture said he is ready to ensure wide-ranging support to woo Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to build its third Japanese chip factory there. Concerns of groundwater shortages when TSMC’s two plants begin operations in the prefecture’s Kikuyo have spurred discussions about the possibility of tapping unused dam water, Kumamoto Governor Takashi Kimura said in an interview on Saturday. While Kimura said talks about a third plant have yet to occur, Bloomberg had reported TSMC is already considering its third Japanese fab — also in Kumamoto — which would make more advanced chips. “We are